Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Myogen (MYOG) -- Ignore unavailable to you. Want to Upgrade?

To: tuck who wrote (12)	1/23/2006 4:13:30 AM
From: kenhott	Respond to of 50

<What I do not know for sure is at what doses the LFTs occurred.> 12-week blinded period to doses of 1, 2.5, 5 and 10 mg po qd, followed by a 12-week open-label dose adjustment period. ambrisentan stat significant vs. baseline 6MWD in all four dose groups at week 12. Four patients developed transient elevations of serum aminotransferases >3X ULN during 24 weeks: One (>8X ULN) required drug discontinuation, one dose reductions, and two elevations were not confirmed by retesting. Adverse events were not dose-related... No additional ALT problem observed during the first year. At study end, 48% were receiving 10 mg/day, none of whom developed elevations >3X ULN. <AMB-222> 2.5mg for 4 weeks then 5mg. Results in Feb 06. +++++++++ dose/titration vs. efficacy vs. ALT.